Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children

• Main Authors: Paula Zapata-Cobo (Author), Sara Salvador-Martín (Author), Marta Velasco (Author), Laura M. Palomino (Author), Susana Clemente (Author), Oscar Segarra (Author), Ana Moreno-Álvarez (Author), Ana Fernández-Lorenzo (Author), Begoña Pérez-Moneo (Author), Montserrat Montraveta (Author), Cesar Sánchez (Author), Mar Tolín (Author), Inés Loverdos (Author), María Jesús Fobelo (Author), Victor Manuel Navas-López (Author), Lorena Magallares (Author), Ruth García-Romero (Author), José Germán Sánchez-Hernández (Author), Alejandro Rodríguez (Author), Ferrán Bossacoma (Author), María Jesús Balboa (Author), Enrique Salcedo (Author), María Sanjurjo-Sáez (Author), Luis A. López-Fernández (Author)
• Format: Book
• Published: Elsevier, 2023-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Few genetic polymorphisms predict early response to anti-TNF drugs in inflammatory bowel disease (IBD), and even fewer have been identified in the pediatric population. However, it would be of considerable clinical interest to identify and validate genetic biomarkers of long-term response. Therefore...